Andy Johnston, PharmD (Clinical Operations) has clinical experience that spans over 30 years and multiple therapeutic areas. He was previously the Director of Psychiatry Clinical Development for Glaxo Welcome and was instrumental in the initiation and conduct of Glenveigh's DEEP study. Andy had a leading role in the development of bupropion for both depression and smoking cessation.